MetaCap

Connect Biopharma (CNTB) vs Stablecoin Development (SDEV)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Connect Biopharma (CNTB) has outperformed Stablecoin Development (SDEV) over the past year, losing 80.6% versus a loss of 88.4%. Over five years, CNTB leads with a -86.9% price change compared with -100.0% for SDEV. Connect Biopharma is the larger company by market cap ($38.0 million vs $36.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CNTB-80.59%SDEV-88.37%
+2239%+1020%-199%
Nov 21, 20251 yearNov 20, 2026
CNTB-88.48%SDEV-99.98%
+20%-43%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CNTB versus SDEV key metrics
MetricCNTBSDEV
Share price$0.59$0.50
Market cap$38.05M$36.90M
1-day change-6.08%-10.30%
YTD return-79.08%-98.23%
1-year return-80.59%-88.37%
5-year return-86.89%-99.98%
P/E ratio (TTM)—0.19
EPS (TTM)$-1.14$2.70
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$64.00K—
Revenue growth (YoY)-99.75%—
Net income (latest FY)$-55.48M$-630.78M
Operating margin-90740.63%—
Net margin-86687.50%—
52-week high$3.82$99.75
52-week low$0.55$0.467
Distance from 52-week high-84.55%-99.50%
Analyst consensusstrong_buy—
Avg. price target upside+896.61%—
Average volume3.98M16.98M
Shares outstanding64.49M73.80M
Employees642
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Connect Biopharma

CNTB stock →

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).

Health Care · Biotechnology: Pharmaceutical Preparations · 64 employees

About Stablecoin Development

SDEV stock →

Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

CNTB vs SDEV FAQ

Which is bigger, Connect Biopharma or Stablecoin Development?

Connect Biopharma (CNTB) is larger, with a market capitalization of $38.05M compared with $36.90M for Stablecoin Development (SDEV).

Which stock has performed better over the past year, CNTB or SDEV?

CNTB returned -80.59% over the past 12 months, compared with -88.37% for SDEV (price return, excluding dividends). Past performance does not predict future results.

Are Connect Biopharma and Stablecoin Development in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons